Nuwellis (NUWE) Return on Capital Employed (2012 - 2026)
Nuwellis (NUWE) posted Return on Capital Employed of 448.98% for Q1 2026, down 62.47% on a QoQ basis from 276.34% in Q4 2025, and down 28543.0% year-over-year from N/an in Q1 2025.
Nuwellis (NUWE) Return on Capital Employed (2012 - 2026) Analysis & Trends
Nuwellis' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 448.98% for Q1 2026.
- Quarterly Return on Capital Employed fell 28543.0% year-over-year to 448.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 448.98% (down 28543.0% YoY) and the FY2025 annual result came in at 223.96%, down 7256.0% from the prior year.
- Return on Capital Employed was 448.98% for Q1 2026 at Nuwellis, down from 276.34% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 75.29% in Q1 2022 and bottomed at 573.81% in Q2 2024.
- A 5-year average of 228.9% and a median of 191.53% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 42730 bps — and 2025, when it surged 33907 bps.
- Nuwellis' Return on Capital Employed stood at 101.8% in 2022, then slumped by 133 bps to 237.31% in 2023, then rose by 19 bps to 191.53% in 2024, then slumped by 44 bps to 276.34% in 2025, then sank by 62 bps to 448.98% in 2026.
- Business Quant data shows NUWE's Return on Capital Employed at 448.98% in Q1 2026, 276.34% in Q4 2025, and 217.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.91 Bn | 176.62 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 108.72 Bn | 99.50 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 48.53 Bn | 44.85 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn | 24.24% |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn | 9.30% |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.47 Bn | 22.34 Bn | 2.07 Bn | 8.38% |
| 10 | Nuwellis | 116,651.13 | -1.97 Mn | 1.68 Mn | -448.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -448.98% |
| Dec 31, 2025 | -276.34% |
| Sep 30, 2025 | -217.95% |
| Jun 30, 2025 | -234.74% |
| Mar 31, 2025 | -163.54% |
| Dec 31, 2024 | -191.53% |
| Sep 30, 2024 | -324.52% |
| Jun 30, 2024 | -573.81% |
| Mar 31, 2024 | -424.56% |
| Dec 31, 2023 | -237.31% |
| Sep 30, 2023 | -176.86% |
| Jun 30, 2023 | -146.52% |
| Mar 31, 2023 | -106.51% |
| Dec 31, 2022 | -101.80% |
| Sep 30, 2022 | -102.18% |
| Jun 30, 2022 | -88.86% |
| Mar 31, 2022 | -75.29% |
| Dec 31, 2021 | -67.45% |
| Sep 30, 2021 | -69.39% |
| Jun 30, 2021 | -66.02% |